Google
ARCT — ARCTURUS THERAPEUTICS HOLDINGS INC (Healthcare >> Biotechnology)
ARCT FAQ
What is ARCT's ROE?
ARCTURUS THERAPEUTICS HOLDINGS INC reports a Return on Equity (ROE) of -41.11%.
What is ARCT's dividend yield?
ARCTURUS THERAPEUTICS HOLDINGS INC offers a dividend yield of 0.00%.
What is ARCT's Deepscope Quality Score?
Deepscope rates ARCT's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ARCT?
Deepscope's AI Timing Score for ARCT is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ARCT belong to?
ARCTURUS THERAPEUTICS HOLDINGS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.16
Price
0.04
(0.56%)
Day Change
|
|
|---|
ARCT, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.16 |
| PBV / Sector |
1.04 / 4.71
GREAT
|
| Earning Per Share | -2.84 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
3.34 M
GREAT
|
| Average 1W Daily Value |
3.26 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:45 |
| Symbol | ARCT |
| Name | ARCTURUS THERAPEUTICS HOLDINGS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 28.42 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 198.39 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10285 Science Center Drive, San Diego, CA, United States, 92121
Phone: 858 900 2660
Website: https://arcturusrx.com
Employees: 106
Sector: Healthcare >> Biotechnology
Description: Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
